Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P P Bringuier

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Cancer Research|July 15, 1994
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancerR Umbas, W B Isaacs, P P Bringuier, et al.
British Journal of Cancer|July 1, 2010
A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European regionP A Cassier, F Ducimetière, A Lurkin, et al.
Journal of Clinical Pathology|May 30, 2006
Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 casesV Hervieu, F Lepinasse, G Gouysse, et al.
Bulletin Du Cancer|May 28, 2010
[Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region]F Ducimetière, A Lurkin, D Ranchère-Vince, et al.
British Journal of Cancer|July 29, 2010
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosisA Dufresne, F Bertucci, N Penel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Medical Oncology (Northwood, London, England)|September 29, 2011
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTsJ F Emile, S Brahimi, J M Coindre, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cancer Research|July 15, 1994
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancerR Umbas, W B Isaacs, P P Bringuier, et al.
British Journal of Cancer|July 1, 2010
A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European regionP A Cassier, F Ducimetière, A Lurkin, et al.
Journal of Clinical Pathology|May 30, 2006
Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 casesV Hervieu, F Lepinasse, G Gouysse, et al.
Bulletin Du Cancer|May 28, 2010
[Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region]F Ducimetière, A Lurkin, D Ranchère-Vince, et al.
British Journal of Cancer|July 29, 2010
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosisA Dufresne, F Bertucci, N Penel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Medical Oncology (Northwood, London, England)|September 29, 2011
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTsJ F Emile, S Brahimi, J M Coindre, et al.
Pageof 4